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Abstract:  
Introduction 
Mapping algorithms are increasingly being used to predict health utility values based on 
responses or scores for non-preference based measures, thereby informing economic 
evaluations. We explored whether predictions in EQ-5D-3L health utility gains from mapping 
algorithms might differ if estimated using differenced versus raw scores, using the Roland 
Morris Disability Questionnaire (RMQ), a widely-used health status measure for low back 
pain, as an example.  
Methods 
We estimated algorithms mapping within-person changes in RMQ scores to changes in EQ-
5D-3L health utilities using data from two clinical trials with repeated observations. We also 
estimated response mapping algorithms from these data to predict within-person changes in 
responses to each EQ-5D-3L dimension from changes in RMQ scores, using logistic 
regression models. Predicted health utility gains from these mappings were compared with 
predictions based on raw RMQ data. 
Results 
Using differenced scores reduced the predicted health utility gain from a unit decrease in 
RMQ score from 0.037 (standard error (SE) 0.001) to 0.020 (SE 0.002). Analysis of 
response mapping data suggests that use of differenced data reduces the predicted impact 
of reducing RMQ scores across EQ-5D-3L dimensions, and that patients can experience 
health utility gains on the EQ-5D-3L 'usual activity' dimension independent from 
improvements captured by the RMQ. 
Conclusion 
Mappings based on raw RMQ data overestimate the EQ-5D-3L health utility gains from 
interventions that reduce RMQ scores. Where possible, mapping algorithms should reflect 
within-person changes in health outcome and be estimated from datasets containing 
repeated observations if they are to be used to estimate incremental health utility gains.  
 
Key Points for Decision Makers 
The QALYs associated with changes in a non-preference based outcome measure can vary 
substantially if estimated using mapping algorithms based on differenced, rather than raw, 
scores. 
Mappings should be estimated using differenced scores from repeated observations if they 
are to be used to estimate treatment-related incremental QALYs, to avoid the impact of 
confounders unrelated to treatment.  
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1. Introduction 
 
Cost-utility analysis requires health outcomes to be measured on preference-based utility 
scales that reflect values assigned to all possible health states, including perfect health and 
death. It remains the preferred form of economic evaluation by public bodies such as the 
National Institute for Health and Care Excellence NICE in England and Wales (1), as it 
provides a single preference-based scale for assessing diverse health outcomes, and  
allows cost-effectiveness comparisons to made across clinical specialties. Many studies 
collect data on non-preference based measures of health-related quality of life or clinical 
symptoms, without also collecting data on preference-based outcome measures such as the 
EQ-5D-3L or SF-6D. Results from these studies can still inform cost-utility analyses if 
mapping algorithms are available to predict health utility values based on responses or 
scores for non-preference based measures. These mapping algorithms are typically 
constructed from datasets in which participants simultaneously report outcomes for 
preference-based and non-preference-based measures.(2) Such datasets are commonly 
cross-sectional, but examples exist where mappings have been derived from datasets with 
repeated observations on participants.(3, 4) This can increase the precision with which 
mapping coefficients are estimated, as long as the statistical methods used account for 
correlations between observations from the same participant. 
 
The Roland Morris Disability Questionnaire (RMQ) is a commonly-used non preference 
based outcome measure for low back pain.(5) It consists of 24 items relating to a range of 
functions commonly affected by low back pain and disability, each with binary ‘yes’/’no’ 
options. The total number of positive responses is summed to form a score (from 0 to 24), 
and a low score is associated with less disability. We have previously developed mapping 
algorithms translating RMQ scores into EQ-5D-3L and SF-6D response and utility scores, 
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based on repeated observations from two randomised clinical trials, using a range of 
regression models to account for the properties of the distribution of utility scores and the 
relationships between repeated observations.(6) In this paper, we present an alternative 
approach for estimating mapping algorithms between the RMQ and the EQ-5D-3L, using 
individual patient differenced RMQ scores. We use the term ‘differenced’ to refer to the 
change in RMQ score, utility or EQ-5D-3L response between two observations on the same 
individual at two different time points. We compare the direct and response mappings 
derived from these data to mappings constructed using raw data (in this context, we refer to 
raw data as data that has not been processed or manipulated in any way, such as 
differencing), and explore the implications of our findings for economic evaluations of low 
back pain treatments and the construction of mapping algorithms based on non-preference 
based outcome measures in other clinical areas. 
 
 
2. Data and methods 
2.1 Data used for mapping estimation. 
We previously used data from the Back Skills Training (BeST) trial (7) to develop a range of 
mapping algorithms from the RMQ to utility scores derived from the EQ-5D-3L.(6)  BeST 
was a pragmatic, multicentre, randomised controlled trial of a cognitive behavioural 
intervention for low back pain combined with active management, compared with active 
management alone, which recruited 701 participants from 56 general practices in seven 
regions across England.  Individuals were eligible for inclusion if they were aged 18 years or 
older, had at least moderately troublesome sub-acute or chronic low back pain of a minimum 
of 6 weeks duration, and had consulted for low-back pain in primary care within the 
preceding 6 months. The algorithms we developed involved both direct mapping (in which 
RMQ scores were mapped to utility scores derived from EQ5D responses using UK tariffs) 
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and response mapping (in which RMQ scores were mapped to the actual responses to the 
EQ-5D-3L questionnaire), and versions were developed based on the total RMQ score as 
well as responses to individual RMQ items. Models were validated using data from the Back 
Pain Exercise and Manipulation (UK BEAM) trial.(8) The UK BEAM trial recruited and 
randomised 1334 participants presenting in primary care with low back pain to one of four 
interventions: manipulation, exercise, manipulation combined with exercise or best care in 
general practice. Among other criteria, individuals were eligible for inclusion if they were 
aged between 18 and 65 and had a score of four or more on the RMQ on the day of 
randomisation.  Both the BeST and UK BEAM datasets included repeated observations of all 
outcome measures; the BeST trial at randomisation, and 3, 6 and 12 months post-
randomisation, and the UK BEAM trial at randomisation, and 1, 3 and 12 months post-
randomisation. Tables 1 and 2 summarise the data available on within-person changes to 
RMQ and EQ-5D-3L utility scores over the follow-up periods in the BEST and UK BEAM 
trials, respectively. In our previous work, we incorporated these repeated observations using 
robust standard error and hierarchical (random intercept and random coefficient) regression 
models; further details on these models are given in Khan et al. (6) 
2.2 Description of mapping models 
We extended our previous work by initially fitting an Ordinary Least Squares (OLS) 
regression model to the BeST dataset with change in EQ-5D-3L utility score as the 
dependent variable and change in RMQ score as the main explanatory variable. As in our 
previous work,(6) we included age and sex as covariates, and included all participants 
irrespective of trial arm allocation. The regression is therefore given by equation 1: 
 
 1 2 3 4 4 *
U RMQ B B RMQ
ij j j ij j i j i j ij j ij ij ijy s RMQ RMQ                   [1] 
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Here 
U
ij is the change in health utility score experienced by participant i during time interval 
j; 
RMQ
ij is the change in the RMQ score of participant i during that interval; iy and is are the 
age and sex, respectively, of trial participant i, and 
B
ijRMQ  is the RMQ score at the start of 
interval j. *B RMQij ijRMQ   is a term allowing for interaction between 
B
ijRMQ  and 
RMQ
ij , and ij  
is a normally-distributed random variable with mean zero. The time interval j refers to the 
time between successive observations, rather than the time from baseline to a given 
observation. This is to ensure that there is no overlap between time intervals, as such 
overlaps would induce correlations between differenced observations. Were no missing data 
present, there would be three time intervals, reflecting the follow-up intervals in the BeST 
trial: 0-3 months, 3-6 months, and 6-12 months (where 0 denotes the point of trial 
randomisation).  Due to missing observations for some participants, there were three 
additional intervals in the differenced dataset: 0-6 months, 0-12 months and 3-12 months. 
Equation 1 therefore defines 6 independent regression models. We also fitted a seventh 
model in which the regression coefficients were assumed to be equal for each interval, so 
that we could test the assumption that the mapping relationship was stable over time during 
the follow-up period of the BeST trial. We used data from the UK BEAM trial for external 
validation of the models, and drew comparisons of their predictive power with models based 
on raw values rather than differenced scores.   
 
Using the data from the BeST trial, we then fitted a range of response mapping models (9, 
10) for each dimension of the EQ-5D-3L, based on differenced data. These models estimate 
the probability that an individual will report level 1,2 or 3 at a particular follow-up time point 
for each dimension of the EQ-5D, conditional on their response for that dimension at their 
most recent previous observation, and the difference between the RMQ scores reported at 
the current and most recent previous observation. This can be thought of as fitting five state-
transition models, one for each EQ-5D-3L dimension, in which the states are the three 
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possible EQ-5D-3L dimension levels that can be reported. Multinomial regression models 
were used to estimate these probabilities, as a function of the change in RMQ score 
between observations, and any other variables that were found to be significant predictors, 
at the 5% significance level (this level is used to define significance throughout the paper), of 
change in utility score in the OLS regression (equation 1). These models are given by 
equation 2: 
 
 
   
1 1 1
2 2 2 3 3 3
exp
; [ ] 0 , , ,
1 exp exp
ab ab ab
jk jk ij ijkab a a a
ijk jk jk ijka a a a a a
jk jk ij ijk jk jk ij ijk
x
p E a i j k
x x
  
  
     
 
    
     
 
           [2] 
Here 
ab
ijkp is the probability that participant i will provide response level b to item k of the EQ-
5D-3L questionnaire at the end of interval j if they provided response level a at the start of 
that interval. For example, 
2,1
100,2,3p  is the probability that, if participant 100 reported level 2 on 
the Usual Activities dimension of the EQ-5D-3L the second time they completed the 
questionnaire, they would report level 1 on this dimension the third time they completed the 
questionnaire.  ijx  is the vector of explanatory variables identified as significant predictors of 
change in utility score in the previous model, including the change in RMQ over the interval j. 
ab
jk  is the intercept term for the logistic regression predicting 
ab
ijkp  from ijx , 
ab
jk is a vector of 
regression coefficients for the predictors, and
ab
ijk is a normally distributed error term with 
zero mean. The restriction 
1 1 1 0 , , ,a a ajk jk ijk a i j k      ensures that  
1a
ijkp  , 
2a
ijkp , and 
3a
ijkp
sum to 1, which they must always do since the levels 1, 2 and 3 are the only possible 
responses.  
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We compared this response mapping to a response mapping model based on raw RMQ 
scores, as given by equation 3: 
 
 
   
1 1 1
2 2 2 3 3 3
exp
; [ ] 0 , ,
1 exp exp
b b b
k k i ijkb
ijk k k ijk
k k i ijk k k i ijk
x
p E i j k
x x
  
  
     
 
    
     
 
            [3] 
Here 
b
ijkp is the probability that participant i will provide response level b to item k of the EQ-
5D-3L questionnaire at the start of interval j and ix  is the vector of explanatory variables, 
including the RMQ score at the start of interval j, and any patient characteristics included in 
equation 2.  
 
2.3 Illustrative example 
Given the differences in structure between the models described by equations 2 and 3, a 
direct comparison of model coefficients is difficult to interpret. To aid this comparison, we 
carried out an illustrative hypothetical exercise to contrast, for the two models, the predicted 
changes in response levels that would result from an RMQ change that might typically be 
observed in a population with lower back pain. For this exercise, we chose to base our 
hypothetical cohort on the BEST participant population at baseline (n= 675). We then 
compared the predictions from the raw and differenced models described above as to the 
dimension-level responses that would be observed at follow-up in two hypothetical 
scenarios: 
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Scenario 1: The cohort experienced no change in disability from their back pain between the 
initial and follow-up observations ( 0RMQ  ).  
The prediction of dimension scores using the raw scores response mapping model (i.e. 
equation (3)) is straightforward, since equation (3) predicts that EQ-5D-3L responses at 
follow-up will be the same as at the initial observation. This is not true for the differenced 
scores response mapping model, because of the intercept terms in equation 2, and the 
coefficient associated with baseline RMQ. For example, consider an individual in the 
hypothetical cohort who reported level 2 for mobility at the initial observation, and an RMQ 
score of 6 at both initial and follow-up observation. Using the notation of equation 2, this 
implies that a=2, j=1, and k=1, and the probabilities that they will report level 1, 2 or 3 for 
mobility at follow-up are given by: 
   2,2 2,2 2,3 2,31,1 1,1 1 1,1
1
[ 1]
1 exp 6 [2] exp 6 [2]
p mobility
   
 
   
 
 
   
2,2 2,2
1,1 1
2,2 2,2 2,3 2,3
1,1 1,1 1,1 1,1
exp 6 [2]
[ 2]
1 exp 6 [2] exp 6 [2]
p mobility
 
   

 
   
 
 
   
2,3 2,3
1 1
2,2 2,2 2,3 2,3
1,1 1,1 1,1 1,1
exp 6 [2]
[ 3]
1 exp 6 [2] exp 6 [2]
p mobility
 
   

 
   
 
 
Here we define the second element of the 
1
b vector as the coefficient for baseline RMQ, 
which is why it appears in the equations above. 
 
Scenario 2: The cohort experienced a moderate improvement in disability from their back 
pain between the initial and follow-up observation ( 2RMQ   ). 
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We chose a two point reduction in RMQ to represent a moderate improvement in back pain 
disability as this is close to the improvement seen in the BEST population (the mean change 
across all participants in the study over its duration was -2.28).  
The impact of this improvement on the individual described in scenario 1, as predicted by the 
raw score response mapping model, is given by equation 3: 
 
   2 2 3 31 1 1 1
1
[ 1]
1 exp 2 [1] exp 2 [1]
p mobility
   
 
   
 
 
   
2 2
1 1
2 2 3 3
1 1 1 1
exp 2 [1]
[ 2]
1 exp 2 [1] exp 2 [1]
p mobility
 
   

 
   
 
 
   
3 2
1 1
2 2 3 3
1 1 1 1
exp 2 [1]
[ 3]
1 exp 2 [1] exp 2 [1]
p mobility
 
   

 
   
 
 
Here we define the first element of the 
1
b vector as the coefficient for change in RMQ, which 
is why it appears in the equations above. 
 
Using the differenced scores response mapping model would result in the following 
predicted probabilities: 
 
   2,2 2,2 2,2 2,3 2,3 2,31,1 1,1 1,1 1,1 1,1 1,1
1
[ 1]
1 exp 2 [1] 6 [2] exp 2 [1] 6 [2]
p mobility
     
 
     
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 
   
2,2 2,2 2,2
1,1 1,1 1,1
2 2,2 2,2 2,3 2,3 2,3
1,1 1,1 1,1 1,1 1,1 1,1
exp 2 [1] 6 [2]
[ 2]
1 exp 2 [1] 6 [2] exp 2 [1] 6 [2]
p mobility
  
     
 
 
     
 
 
   
2,3 2,3 2,3
1,1 1,1 1,1
2,2 2,2 2,2 2,3 2,3 2,3
1,1 1,1 1,1 1,1 1,1 1,1
exp 2 [1] 6 [2]
[ 1]
1 exp 2 [1] 6 [2] exp 2 [1] 6 [2]
p mobility
  
     
 
 
     
 
 
The sole difference from scenario 1 is the addition of the 2 [1]
ab
jk  terms to alter the 
transition probabilities in light of the RMQ reduction in scenario 2.  
We followed the following steps to generate our illustrative comparison: 
Step 1: Read the baseline RMQ score and response for the mobility dimension for the 1st 
participant in the BEST dataset 
Step 2: Estimate the predicted probability for this individual of reporting each possible level 
for the mobility dimension at follow-up, using the differenced model, assuming RMQ is 
unchanged (scenario 1). 
Step 3: Repeat steps 1 and 2 for each participant in the BEST dataset. 
Step 4: Calculate the mean predicted probability for each level across all BEST participants. 
This is interpreted as the predicted proportion of the hypothetical cohort reporting each level 
at follow up.  
Step 5: Repeat steps 1-4 for all other EQ-5D-3L dimensions 
Step 6: Repeat steps 1-5 assuming a 2-point reduction in RMQ score (scenario 2) 
Step 7: Repeat step 6 using the raw score response mapping model. 
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Step 8: Calculate the proportions of the hypothetical cohort reporting each level for each 
dimension of the EQ-5D-3L. These will also be the predicted proportions from the raw score 
mapping model at follow-up under scenario 1. 
 
Following these steps, we were able to compare and contrast the predicted change in these 
proportions from either model in either scenario, and illustrate how the raw and differenced 
score models would yield different EQ-5D response predictions for a treatment that yielded 
an improvement in back pain disability resulting in a 2-point reduction in RMQ. 
 All statistical analyses described above were performed in R (version 3.0.1). 
 
3. Results 
3.1. Direct mapping models 
Tables 1 and 2 provide information on the number of observations available in the BeST and 
UK BEAM datasets at the different follow-up points and also present the mean changes in 
RMQ and EQ-5D-3L utility scores over the alternative time intervals. There were 701 
patients recruited to the BeST trial, and three follow-up time points, giving a maximum of 
2103 possible data observations, of which 1476 (70.2%) were actually collected. A 
differenced score was only calculated for an interval if the individual had provided both RMQ 
and EQ-5D-3L data at both the start and the end of the interval. If an individual had failed to 
provide responses at 3 months for RMQ and/or EQ-5D, but had done so at 0, 6 and 12 
months, they would contribute an observation for the 0-6 and 6-12 month intervals only.  
Table 2 gives the coefficients for OLS regression models predicting the change in utility 
score between successive observations of BeST trial participants. The first column in table 2 
presents the results from fitting an OLS regression model using all 1476 observations. The 
predicted decrease (increase) in EQ-5D-3L health utilities from a 1-point increase (decrease) 
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in RMQ score from this model is 0.020 (p<0.01). Age and sex were not significantly 
associated with changes in EQ-5D-3L utility score, but the baseline RMQ co-efficient of -
0.003 was significant (p=0.001) . This co-efficient, together with the intercept, determines the 
predicted change in utility if RMQ does not change between observations. The intercept 
gives the predicted utility score change if the RMQ score at the start of an interval is 9 (the 
baseline mean for the BEST dataset), and does not change. The intercept is negative, 
suggesting that utility declines if the RMQ score does not change, although the term is not 
significant. However, the coefficient for RMQB is negative, implying that the more severe the 
condition initially (higher RMQ is equivalent to greater disability), the greater the utility loss 
associated with no improvement in back pain disability. The interaction term was not 
significant, suggesting that the change in utility per unit change in RMQ is independent of 
baseline RMQ.  
 
 Table 2 also includes results from fitting separate OLS regressions for each time interval. 
The slope coefficient of 0.20 derived from fitting the single OLS regression across time 
intervals lies within each of the slope coefficient confidence intervals obtained by fitting 
separate OLS regressions for each time interval, which is consistent with the assumption 
that the coefficient mapping changes in RMQ with changes in utility is stable over time. We 
also explored a reduced form of this model in which the specific time interval between 
observations was included as a six-level factor (taking values from 1 to 6); none of these 
levels were significantly associated with the change in EQ-5D-3L utility score. Values for 
other coefficients were broadly consistent across intervals, with differences that were 
consistent with sampling variation. The exception was the interaction term, which was 
statistically significant for the 3-6 month and 3-12 month intervals.  
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Figure 1 illustrates how the relationship between RMQ score change and EQ-5D-3L utility 
score change predicted by the model described above, which involves regressing  
differenced utility score on differenced  RMQ score (the ‘OLS differenced score model’),  
compares with predictions from algorithms based on raw score data. In our previous work 
we found that a beta regression multi-level model fitted to baseline and follow-up 
observations was the strongest-performing model.(6) Figure 1 compares the results of this 
model to the OLS model presented in table 1. The predicted impact of a unit change in RMQ 
score on health utility is approximately 50% lower when based on differenced rather than 
raw score data as in our previous work (0.019 vs 0.037). However, this is not a direct 
comparison of mapping algorithms derived from changes in RMQ scores with mapping 
algorithms derived from RMQ scores at a single time point, since the beta regression 
algorithm draws on repeated observations and uses a different regression method to the 
OLS intervals model. To allow for direct comparison, Figure 1 also includes predictions from 
an OLS model fitted to baseline data alone. This shows that the adoption of beta rather than 
linear regression and the inclusion of repeated observations have little impact on the 
discrepancy, especially for low-to-moderate changes in RMQ score. Figure 1 further depicts 
the actual relationship between differenced RMQ and utility observed in the BEST trial, from 
which the improvement in fit from modelling differenced data directly can be clearly seen.   
Table 2 presents the results from external validation of the three models illustrated in Figure 
1, using separate data from the UK BEAM trial. Model fit is assessed by calculating root 
mean square error (RMSE) for predicted changes in utility scores between time-points in the 
UK BEAM trial. The OLS differenced scores model results in a 0.02 reduction in RMSE 
compared with the raw score OLS model.  
3.2 Response mapping models 
Table 3 provides fitted values from the response mapping state transition models predicting 
changes in reported levels in each EQ-5D-3Ldimension between observations. Based on the 
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results of fitting the direct mapping differenced model, only RMQB and 
RMQ
ij were included 
as explanatory covariates for the response mapping model. Probabilities are not given for 
transitions between levels one (‘no problems’) and three (‘severe or extreme problems’) as 
there were too few such transitions (< 5) for their estimation. For the same reason, 
probabilities are not given for transitions to or from level three for the EQ-5D-3L‘mobility’ and 
‘self care’ dimensions.  The results suggest that there is a non-trivial possibility of changing 
level even when the RMQ score remains unchanged, the probability of which will depend on 
this RMQ score, since it is included as a covariate. Table 3 presents these probabilities 
assuming RMQ values of 9 (the mean at baseline in the BEST dataset), as well as 5 and 12 
(the interquartile values in the BEST dataset).  This probability is greatest for those reporting 
level 1 on the EQ-5D-3L pain dimension, who have a 97% chance of reporting level 2 on that 
dimension at the next observation if their RMQ score remains unchanged at 9. By contrast, 
93% of those reporting level 1 on the EQ-5D-3L self-care dimension continue to report that 
level if their RMQ score remains unchanged at 9. 
 
The odds ratios presented in the final column of table 3 can be used to estimate the change 
in probabilities of each transition associated with a given change in RMQ score. For 
example, each 1-point increase in RMQ (i.e. worsening in back pain disability is associated 
with a 20% increase in the odds of reporting some mobility problems (level 2) for someone 
who had not reported any mobility problems before their RMQ increased.  The impact of a 
reduction in RMQ is equal in magnitude, but opposite in sign. Overall, an increase in RMQ 
score (representing an increase in back pain related disability) is associated with an 
increased change of reporting worsening health on all EQ-5D-3L dimensions. There is a 
suggestion, however, that anxiety is less influenced by RMQ score changes than other EQ-
5D-3Ldimensions, as the mean odds ratios for this dimension are lower than for the others.  
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In order to determine whether specific EQ-5D-3L dimensions were driving the discrepancy 
illustrated in Figure 1, it is necessary to compare the predictions of this model from those 
from a standard response mapping model fitted to baseline (point of randomisation) raw 
score/level data only. Table 4 lists the coefficients for such a model. One obvious difference 
is that the model presented in table 4 does not permit changes in level when the RMQ score 
remains unchanged. Further comparison of the coefficients presented in tables 3 and 4 is of 
limited value, given the differences in structure between the two response mapping models. 
For this reason, we constructed our illustrative model, the results of which are presented in 
table 5. For the illustrative example, the raw score response mapping model predicts EQ-5D-
3L utility scores to be more sensitive to RMQ score changes than the differenced score 
model for all dimensions, with the greatest discrepancy for anxiety/ depression and pain.   
Estimates are also provided of movements predicted by the differenced score response 
mapping model in EQ-5D-3L responses in the absence of any change in RMQ score. The 
predicted increase in the proportion reporting ‘no problems’ for usual activities, given no 
change in RMQ score, is 9%. The equivalent change in proportions for other EQ-5D-3L 
dimensions is 5% or less. 
 
4. Discussion 
 
The development and use of mapping algorithms has become increasingly common, 
particularly following the publication, in 2008, of NICE methods guidance endorsing the use 
of such algorithms when directly measured EQ-5D-3L utilities are unavailable.(3) Detailed 
methods guidance has recently been published on the development of mapping algorithms 
for use in economic evaluations.(11, 12) This guidance covers a wide range of issues such 
as the comparability of populations for estimation and validation, the inclusion of covariates, 
and the choice of statistical models. No guidance is provided, however, on the use of cross-
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sectional versus longitudinal data, or the appropriate statistical techniques for analysing the 
latter. Our work is the first, to our knowledge, to compare mapping algorithms based on 
within-person changes in scores with those based on raw data. We also present a novel 
state-transition approach to response mapping between changes in a widely used clinical 
score for disability due to low back pain (13) and changes in EQ-5D-3L dimension levels.  
4.1 Why using differenced data alters the mapping algorithm 
We observed that using within-person changes in RMQ scores reduces the predicted EQ-
5D-3L health utility decrement of a unit increase in RMQ score by approximately 50%. This 
suggests that factors, such as comorbidities, may independently increase the disability 
associated with low back pain in those with lower health utilities. Such factors will lead to 
potential over-estimation of the health utility benefits from treatments that alleviate low back 
pain by mappings based on raw data. For example, it may be that those with anxiety or 
depression unrelated to their back pain tend to experience greater functional impairment 
from low back pain. Alleviating this functional impairment may reduce raw RMQ scores 
without necessarily improving mental wellbeing. Examination of relationships at the level of 
EQ-5D-3L dimensions can provide insights into which of these reasons are most relevant in 
a specific example. Results reported in table 5 are consistent with the mechanism suggested 
above, but suggest that analysis of cross-sectional data over-estimates the impact of 
changing RMQ scores across all EQ-5D-3L dimensions.  The differenced score response 
mapping model also predicts how EQ-5D-3L responses might change even if the RMQ score 
does not. For individuals, the predicted response at follow-up, conditional on RMQ remaining 
constant, may involve improvement or worsening, depending on the initial response. 
However, the net predicted effect for the BeST population is for minimal change in 
responses if the RMQ score does not change. The possible exception is ‘usual activities’, 
where the predicted increase in those reporting ‘no problems’ would be 9% if the RMQ score 
remained unchanged. This is consistent with NICE guidelines on back pain, which 
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recommend that patients are encouraged to ‘… continue with normal activities as far as 
possible’.  (14)    
4.2 Study limitations 
While our example illustrates the value of basing mapping algorithms on changes in scores 
for source measures, it does have limitations. We were only able to include a limited number 
of covariates in our mapping algorithms (age and sex). We felt that the influence of these 
covariates on predicted utility was too weak to justify their inclusion in the final version 
presented here, although we accept that expert judgement has a role to play in this decision, 
and versions of the response mapping algorithms with these covariates included are 
available from the authors on request. It is possible that inclusion of additional covariates in 
the baseline mapping algorithm would eliminate some of the discrepancy with the 
differences-based algorithm.  
 
We did not find strong evidence to suggest that the relationship between differenced RMQ 
and utility scores varied over the duration of follow-up in BEST (12 months), suggesting that 
the differenced model could be applied to RMQ data collected over any time interval up to 12 
months. Analysis of additional data would allow us to further test this conclusion, and explore 
whether the relationship is stable for intervals longer than 12 months. It may be that this 
stability occurs because the changes in back pain symptoms at different times produce 
similar effects on health-related quality of life. In other conditions, the impact of clinical 
symptoms on the dimensions of health-related quality of life might vary over the life history of 
the illness, so that changes that appear of similar magnitude in a clinical measure might 
produce different utilities at different stages in the disease. Further work applying the 
differencing approach in other disease areas would allow this to be tested.   
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Our study included 1476 observations, which is greater than the median sample size (1167) 
in the mapping studies identified in the recent review by Dakin et al. of studies mapping 
between clinical or health-related quality of life measures and the EQ-5D.(3) However, 
response mapping models tend to need larger samples than direct utility mapping models for 
reliable estimation, since they contain more parameters. Our state-transition response 
mapping model has more parameters still. While we had sufficient observations to estimate 
most transitions, we could not estimate transitions between levels 1 and 3 for any of the 
dimensions. A larger sample size would have allowed us to be more definitive in our 
comparison with the baseline response mapping model, and provide more accurate 
parameter estimates for certain transitions such as those from level 3 in the usual activities 
dimension.  
 
We have used OLS regression to develop our mapping algorithms, and the limitations of this 
model when predicting health utility data have been extensively documented in the 
literature.(2)  While limitations such as ceiling effects and multi-modality are less prominent 
when modelling changes in health utility, it is still possible that a more sophisticated model 
would improve the accuracy of the change-in-scores model. It would also allow us to relax 
the assumption that a unit change is RMQ has the same implications for health utility 
independent from baseline RMQ.  However, given the improvements in model accuracy 
seen in our previous work, it is very unlikely that such models would change the nature of 
our conclusions.  
 
We validated our algorithm using an independent dataset generated by the UK BEAM trial. A 
comparison of the demographic characteristics of participants in the UK BEAM and BEST 
trial has been previously published [6]. The UK BEAM trial was chosen because of 
similarities in participant characteristics and setting with the BEST trial (patients with low 
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back pain presenting in a UK general practice setting, 12 month follow up, similar gender 
balance (BEST 60% vs UK BEAM 56%), similar rates of loss to follow up (BEST 28% vs UK 
BEAM 24% at 12 months) ). The pragmatic nature of both studies, and the primary care 
setting, meant that both populations were broadly representative of the general lower back 
pain population. However, there were some differences in participant demographics – the 
mean age of UK BEAM participants was lower (43 vs 54 years), and while the median RMQ 
was identical in both studies (8), the minimum RMQ score in the UK BEAM trial was higher 
(4 vs 0). Also, the interventions in each trial were qualitatively different, as BEST involved a 
psychological therapy (CBT), whereas UK BEAM involved physical therapies (exercise and 
spinal manipulation). Despite these differences, UK BEAM provides useful validation for our 
analysis, although further validation with other datasets would provide additional 
reassurance.  
4.3 Implications for future mapping studies 
Despite these caveats, our results provide a useful illustration of the potential impact of using 
within-person differences between observations, rather than the raw scores, when 
developing mapping algorithms. The former gives the impact of a change in a non-
preference based health-related quality of life or clinical measure on health utility for an 
individual, whilst the latter generates the predicted difference in health utilities, at given point 
in time, between two individuals with different clinical scores. These are clearly different 
processes, and the appropriate choice depends on the use to which the algorithm will be put. 
For economic evaluations aiming to inform decisions around the adoption of new treatments, 
it is often changes in health utility which are relevant to decision-makers. Our findings 
suggest that, in such cases, mapping algorithms should reflect within-person changes in 
health outcome and be developed using longitudinal data wherever possible. 
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Table 1: Summary of between-observation data from the BEST trial 
Interval 
between 
follow-ups 
(months) 
All 
Intervals 
0*-
3months 
3-
6months 
6-
12months 
0*-
6months 
0*-
12months 
3-
12months 
Number of 
observations 
over this 
interval 
1476 488 445 439 61 26 17 
Mean (SD) 
RMQ  
-0.743 
(3.731) 
-1.715 
(4.022) 
-0.245 
(3.389) 
-0.009 
(3.195) 
-1.852 
(4.892) 
-1.077 
(4.214) 
-0.294 
(4.41) 
Mean (SD) 
U  
0.010 
(0.243) 
0.028 
(0.257) 
0.004 
(0.236) 
-0.003 
(0.231) 
0.038 
(0.250) 
-0.013 
(0.229) 
-0.041 
(0.299) 
*O denotes point of randomisation into the BeST trial. SD = standard deviation. 
RMQ = change in RMQ between observations. U = change in EQ-5D utility 
between observations. 
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Table 2: Summary of coefficients from OLS regression models predicting change in EQ-5D-3L health utility score between follow-up observations 
in the BEST trial, with results from validation using data from the UK BEAM trial. 
Results from fitting models to BeST Data 
Interval between follow-
ups 
All 
 intervals 
0-3  
months 
3-6  
months 
6-12 
months 
0-6  
months 
0-12 
 months 
3-12 
 months 
Number of observations 
over this interval 
1476 488 445 439 61 26 17 
Intercept 
Coefficient (se) 
-0.019 
(0.026) 
0.041 
(0.048) 
-0.034 
 (0.045) 
-0.004 
 (0.046) 
-0.098 
 (0.120) 
-0.094 
 (0.281) 
-0.284 
(0.209) 
RMQ Coefficient (se) -0.020* 
(0.002) 
-0.020 * 
(0.003) 
-0.026* 
 (0.003) 
-0.020* 
 (0.004) 
-0.008 
 (0.007) 
-0.008  
(0.0132) 
-0.034 
(0.016) 
Age 
Coefficient (se) 
0.000 
(0.000) 
-0.001  
(0.001) 
0.000 
 (0.001) 
0.000  
(0.000) 
0.002 
 (0.002) 
0.001 
 (0.004) 
-0.002 
(0.004) 
Sex 
Coefficient (se) 
0.011 
(0.012) 
0.026 
 (0.023) 
0.011 
 (0.022) 
0.042 
 (0.022) 
0.060 
 (0.066) 
0.006 
 (0.119) 
0.255  
(0.137) 
RMQ B 
Coefficient (se) 
-0.003* 
(0.001) 
-0.001 
(0.003) 
-0.002 
(0.002) 
0.006 * 
(0.002) 
0.005  
(0.008) 
-0.005  
(0.011) 
-0.011  
(0.012) 
RMQB  x 
RMQ  
Coefficient (se) 
0.000 
(0.000) 
0.000 
(0.000) 
-0.002* 
(0.001) 
0.000 
(0.001) 
0.000 
(0.001) 
0.001  
(0.003) 
-0.005*  
(0.002) 
                             Results from validating models using UK BEAM data  
Interval between follow-
ups  
All intervals 0-1  
months 
1-3  
months 
3-12 
 months 
0-3 
 months 
0-12 
 months 
1-12  
months 
Number of observations 
over this interval 
2130 739 668 610 42 19 52 
Mean (SD) 
RMQ  -1.212* 
(3.867) 
-1.984*  
 (3.803) 
-1.186* 
  (3.793) 
-0.285 
(3.754) 
-2.357*  
(3.570) 
-2.579 
 (4.694) 
-0.024  
(4.276) 
Mean (SD) 
U  0.025* 
(0.230) 
0.045* 
 (0.238) 
0.035* 
 (0.204) 
0.000 
 (0.229) 
0.030  
(0.286) 
0.011  
(0.279) 
-0.074 
 (0.315) 
RMSE:  
Differenced score model 
0.213 0.227 0.187 0.209 0.254 0.235 0.291 
RMSE:  
Beta regression model 
0.214 0.228 0.186 0.212 0.247 0.253 0.304 
RMSE:  
Raw score model 
0.215 0.231 0.189 0.211 0.248 0.246 0.301 
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* denotes values significantly different from 0 at the 5% significance level.
RMQ = change in RMQ between observations. U = change in EQ-5D utility 
between observations. RMQB = RMQ score at start of interval. Intercept = predicted 
U when 0RMQ  and RMQB = 9 
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Table 3: Results from fitting the state transition response mapping model to differenced data from the BEST trial. 
EQ-5D-3L 
Dimension 
Transition Number 
observed 
in 
dataset 
Probability of transition if RMQ unchanged* 
Estimate (95% CI) 
Reference 
Transition* 
(No. 
observed in 
brackets) 
Change in odds ratio (relative to 
reference transition)  per unit 
change in RMQ 
 
Estimate (95% CI) 
   RMQ = 5 RMQ = 9 RMQ = 12   
Mobility 
1 -> 2 585  
0.18 (0.14,0.23) 
0.39 (0.32,0.47) 0.59 (0.52,0.67) 1 -> 1 
(124) 
1.32 (1.23,1.41) 
2 -> 2 574  
0.64 (0.59,0.69) 
0.82 (0.78,0.85) 0.9 (0.88,0.92) 
 
2 -> 1 
(189) 
1.30 (1.23,1.37) 
Self 
care 
1 -> 2 1145  
0.03 (0.02,0.04) 
0.07 (0.05,0.09) 0.13 (0.1,0.16) 
 
1 -> 1 
(75) 
1.32 (1.23,1.37) 
2 -> 2 162 0.48 (0.39,0.57) 0.63 (0.55,0.71) 0.73 (0.66,0.8) 2 -> 1 
(84) 
1.25 (1.10,1.27) 
Usual 
activities 
1 -> 2 120  
0.29 (0.21,0.38) 
0.53 (0.43,0.63) 0.71 (0.62,0.79) 1 -> 1 
(379) 
1.28 (1.18,1.39) 
2 -> 2 664  
0.66 (0.6,0.71) 
 
0.85 (0.82,0.87) 0.91 (0.88,0.91) 
 
2 -> 1 
 (237) 
1.31 (1.24,1.39) 
2 -> 3 29  
0.01 (0,0.01) 
0.02 (0.01,0.02) 
 
0.03 (0.02,0.05) 
 
2 -> 1 
(237) 1.80 (1.59,2.03) 
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3 -> 3 11  
0.23 (0.07,0.56) 
0.25 (0.07,0.59) 0.27 (0.08,0.61) 
 
3 -> 2 
(32) 1.22 (0.95,1.58) 
Pain 
1 -> 2 43  
0.82 (0.35,0.97) 
0.97 (0.78,1) 0.99 (0.93,1) 1 -> 1 
(41) 
1.50 (1.14,1.97) 
2 -> 2 989  
0.93 (0.89,0.95) 
 
0.90 (0.90,0.90) 
 
0.8 (0.8,0.8) 
 
2 -> 1 
(101) 
1.67 (1.48,1.89) 
2 -> 3 97  
0.03 (0.03,0.03) 
0.09 (0.09,0.10) 
 
0.1 (0.1,0.2) 
 
2 -> 1 
(101) 
2.16 (1.88,2.48) 
 
3 -> 3 110  
0.31 (0.23,0.4) 
0.44 (0.34,0.55) 0.55 (0.45,0.65) 
 
3 -> 2 
(92) 
1.21 (1.11,1.31) 
Anxiety or 
depression 
1 -> 2 162  
0.23 (0.2,0.28) 
0.24 (0.20,0.28) 0.24 (0.2,0.28) 1 -> 1 
654 
1.08 (1.04,1.12) 
2 -> 2 383 
0.61 (0.57,0.65) 
 
0.69 (0.66,0.71) 
 
0.73 (0.71,0.74) 
 
2 -> 1 
(170) 
1.12 (1.06,1.18) 
 
2 -> 3 37 
0.04 (0.03,0.05) 
 0.06 (0.05,0.08) 
0.07 (0.06,0.1) 
 
2 -> 1 
(170) 
1.24 (1.12,1.37) 
 
3 -> 3 34  
0.51 (0.35,0.67) 
0.54 (0.37,0.69) 0.55 (0.38,0.71) 
 
3 -> 2 
 (34) 
1.06 (0.95,1.20) 
31 
 
*The odds of each transition in the table are compared with the odds for the reference transition to calculate an odds ratio which is then adjusted for change in 
RMQ using the change in odds ratio reported in the next column. 
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Table 4: Results from a response mapping model relating EQ-5D-3L dimensions to raw RMQ scores using baseline observations from the BEST 
trial only 
EQ-5D-3L 
Dimension 
Level Probability of reporting 
this level if RMQ = 9 
Change in odds (compared to 
level 1) per unit change in 
RMQ 
 
Mean (95% CI) 
Mobility 
1 0.35 (0.31,0.40) NA 
2 0.65 (0.60,0.69) 1.28 (1.22,1.34) 
3 NA NA 
Self care 
1 0.86 (0.83,0.89) NA 
2 0.14 (0.11,0.17) 1.33 (1.26,1.4) 
3 NA NA 
Usual activities 
1 0.16 (0.14,0.19) NA 
2 0.84 (0.81,0.86) 1.31 (1.23,1.39) 
3 0.02 (0.01,0.03) 1.69 (1.52,1.87) 
Pain 
1 0.02 (0.01,0.03) NA 
2 0.86 (0.85,0.87) 1.22 (1.05,1.42) 
3 0.12 (0.11,0.12) 1.6 (1.37,1.87) 
Anxiety or 
depression 
1 0.51 (0.47,0.53) NA 
2 0.46 (0.43,0.49) 1.13 (1.09,1.18) 
3 0.03 (0.02,0.05) 1.36 (1.25,1.47) 
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Table 5: Comparison of predictions from response mapping models based on raw vs. differenced score data from the BEST trial 
EQ-5D-3L 
Dimension 
Level Probability of reporting this 
level at baseline  
Probability of reporting this 
level at follow-up  if 0RMQ    
Probability of reporting this level  
at follow-up  if 2RMQ    
Predicted incremental impact of 
a 2-point reduction in RMQ 
   Raw score Differenced 
score 
Raw score Differenced  
score 
Raw score Differenced score 
Mobility 
1 0.41 0.41 0.41 0.50 0.48 0.09 0.07 
2 0.59 0.59 0.59 0.50 0.52 -0.09 -0.07 
3 NA NA NA NA NA NA NA 
Self care 
1 0.81 0.81 0.79 0.87 0.83 0.06 0.04 
2 0.19 0.19 0.21 0.13 0.17 -0.06 -0.04 
3 NA NA NA NA NA NA NA 
Usual 
activities 
1 0.22 0.22 0.31 0.30 0.39 0.08 0.08 
2 0.74 0.74 0.66 0.67 0.59 -0.07 -0.07 
3 0.04 0.04 0.03 0.03 0.02 -0.01 -0.01 
Pain 
1 0.03 0.03 0.03 0.04 0.07 0.01 0.04 
2 0.80 0.80 0.75 0.84 0.75 0.04 0.01 
3 0.17 0.17 0.22 0.12 0.17 -0.05 -0.05 
Anxiety or 
depression 
1 0.52 0.52 0.52 0.58 0.55 0.06 0.03 
2 0.44 0.44 0.43 0.39 0.41 -0.05 -0.02 
3 0.05 0.05 0.06 0.03 0.05 -0.02 -0.01 
Raw score results are derived from the response mapping model presented in table 3. Differenced score results are derived from the state transition mapping 
model presented in table 4.  
  
34 
 
Figure Legends 
 
Figure 1: Relationship between changes in RMQ and health utility as predicted by models fitted to BEST raw and differenced data  
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Figure 1 
 
 
